Merkel Cell Carcinoma Epidemiology Forecast 2026-2035

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

Germany

High-Risk Population

Individuals aged over 70 years, particularly older men with fair skin and substantial cumulative ultraviolet (UV) radiation exposure, constitute the principal high-risk population for Merkel cell carcinoma (MCC).

Key Diagnostic Method

Histopathological examination of a skin biopsy, supported by immunohistochemistry (IHC), is the primary diagnostic method for Merkel cell carcinoma (MCC).

Major Risk Factor

Chronic ultraviolet (UV) radiation exposure is a major modifiable risk factor for Merkel cell carcinoma (MCC), contributing to DNA damage and malignant transformation in skin cells.

Major gap in the market

A major unmet need in the Merkel cell carcinoma (MCC) treatment market is the lack of effective, durable treatment options for patients with advanced disease who develop resistance to immune checkpoint inhibitors or cannot tolerate immunotherapy.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

MCC is a rare malignancy, and international epidemiological studies predominantly report incidence, mortality, and survival rather than global point prevalence. A systematic review published in the British Journal of Dermatology in 2024 synthesized population-based evidence from 52 studies across 24 countries, confirming substantial geographic variation and an overall increasing incidence trend. For context, the United States diagnoses approximately 3,000 new cases annually, while England reports around 360 new cases per year based on 2019, 2021, and 2022 data.

Gender-Specific Cases of the Disease

A 2025 population-based study using the U.S. Surveillance, Epidemiology, and End Results (SEER) database identified 11,574 patients diagnosed between 2000 and 2021, of whom 7,368 (63.7%) were male and 4,206 (36.3%) were female. The male predominance is also reflected in incidence rates: a U.S. analysis reported age-adjusted incidence rates of 0.94 per 100,000 person-years in males and 0.46 per 100,000 person-years in females during 2012–2016.

Age-Specific Cases of the Disease

A 2025 U.S. population-based study using the Surveillance, Epidemiology, and End Results (SEER) database identified 11,574 patients diagnosed between 2000 and 2021, with a median age at diagnosis of 77 years. Approximately 72% of cases occur in individuals aged 70 years and older. The highest incidence is observed among adults aged 85 years and above, with 2012–2016 U.S. age-adjusted incidence rates reaching 14.6 per 100,000 person-years in men and 5.5 per 100,000 person-years in women in this age group.

Ethnicity-Wise Cases of the Disease

A 2025 U.S. population-based study using the Surveillance, Epidemiology, and End Results (SEER) database identified 11,574 patients diagnosed between 2000 and 2021; approximately 89.8% of patients with known race were White. A separate SEER cohort of 9,557 patients diagnosed between 2000 and 2018 reported 8,590 White patients (89.9%), 541 Hispanic patients (5.7%), 222 Asian American or Pacific Islander patients (2.3%), 146 Black patients (1.5%), and 58 patients (0.6%) classified as other or unknown race.

Mortality and Survival Analysis of the Disease

A 2025 population-based U.S. study using the Surveillance, Epidemiology, and End Results (SEER) database identified 11,574 patients diagnosed between 2000 and 2021, reporting a median overall survival of 45 months. The age-adjusted mortality rate averaged approximately 0.16 deaths per 100,000 person-years after 2010, with mortality stabilizing and declining slightly. According to the American Cancer Society's 2025 survival estimates, based on patients diagnosed during 2015–2021, the five-year relative survival rate was 79% for localized disease, 66% for regional disease, and 31% for distant metastatic disease, with an overall rate of 69%.

Country

Key Insights

United States

A 2025 population-based study using the Surveillance, Epidemiology, and End Results (SEER) database identified 11,574 patients diagnosed between 2000 and 2021. The age-adjusted incidence rate averaged 0.68 cases per 100,000 person-years during 2013–2021, equivalent to approximately 7 new cases per million people annually.

Germany

A 2024 study published in Cancers analyzed 2,164 newly diagnosed patients between 2008 and 2021 across a population of approximately 18 million. The age-standardized annual incidence was 5.2 cases per million person-years in men and 3.8 cases per million person-years in women, equivalent to 0.52 and 0.38 cases per 100,000 person-years, respectively. Incidence increased substantially with age, reaching 96.1 cases per million person-years among men and 68.4 among women aged 85 years and older.

France

Merkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine malignancy, with population-based French cancer-registry data reporting an age-standardized incidence rate of approximately 0.25 cases per 100,000 person-years. A study published in the British Journal of Dermatology in 2024 reviewed population-based evidence and confirmed that MCC incidence has increased across several European countries. French registry data covering 2006–2010 reported standardized incidence rates of 0.26 per 100,000 person-years in men and 0.24 in women using the European standard population.

Italy

A 2023 study published in the European Journal of Cancer Prevention analysed cases diagnosed in Tuscany between 2006 and 2021 and reported a crude incidence rate of 1.15 cases per 100,000 inhabitants per year during the study period, reflecting a substantial increase in diagnoses in the later years. Separately, a multicentre study of six dermatology clinics in Central Italy identified 94 patients diagnosed between 2015 and 2020 and estimated an incidence rate of 0.93 per 100,000 inhabitants annually.

Spain

Merkel cell carcinoma (MCC) is a rare, aggressive skin malignancy, with a Spanish multicentre observational study published in Cancer Epidemiology in 2022 estimating an incidence rate of 0.32 cases per 100,000 inhabitants annually during 2012–2016. The study included 192 patients from 25 Spanish hospitals and reported regional variation, with higher incidence in northern Spain (0.46 per 100,000) than in central and southern regions (0.28 per 100,000). The mean age at diagnosis was 78.9 years, and 54.2% of patients were male.

United Kingdom

Merkel cell carcinoma (MCC) is a rare, aggressive skin malignancy, with approximately 360 new cases diagnosed annually in England, based on the average for 2019, 2021 and 2022. A national population-based study published in the British Journal of Dermatology in 2023 identified 3,775 MCC tumours diagnosed in England between 2004 and 2018. The European age-standardized incidence rate increased from 0.43 to 0.65 cases per 100,000 person-years over this period, representing an annual increase of 3.9%.

Japan

A nationwide population-based study published in Cancer Science in 2023, using Japan’s National Cancer Registry data for 2016–2017, reported an age-standardized incidence rate of 0.038 cases per 100,000 person-years using the World Health Organization standard population, equivalent to approximately 0.38 new cases per million people annually. Using the Japanese standard population, the age-adjusted incidence rate was 0.17 per 100,000 person-years. A systematic review of 847 Japanese cases diagnosed between 1985 and 2015 reported a mean age at diagnosis of 77.5 years, confirming that MCC predominantly affects older adults.

India

Merkel cell carcinoma (MCC) is an exceptionally rare skin malignancy in India. The latest comprehensive Indian cancer-registry analysis, published in JAMA Network Open in August 2025, analysed cancer data from 43 population-based registries and provided national estimates for 2024. However, it did not report a separate national prevalence estimate for MCC. A 2026 Indian case report published in the Journal of Medical Sciences and Health further documents the continued occurrence of this malignancy in clinical practice.